Strong buying at the end of a year of INSM shares will lead to dizzying returns next year. Arikace is on track, and the billion dollar potential is only starting to get acknowledged. Just wait till the Russell run-up begins... We may qualify for more inclusions than last time!
Russell inclusion next year could be absolutely insane compared with our previous inclusions.
With our inclusion last year, very few of the shares allocated to the VCs were unrestricted at the end of May - and thus were not counted when our market cap was calculated to establish our position in the Russell 3000. The higher the position, the greater the number of shares the tracker funds must hold.
This time round all, of the VC shares will be counted.
And if, by the end of May, it should happen that the top-line data from both the dog toxicity study and the EU clinical trial have been released, and if by that point it has been confirmed that Arikace will be assigned a "breakthrough" designation under the recent legislation, the share price imo will be somewhere north of $50 when our market cap is calculated.
My gut feeling is that somewhere north of 20 million shares would have to be acquired next June on behalf of the tracker funds if all three of the criteria I mention are in place by the end of May.